Literature DB >> 2309841

Placental transfer of indomethacin in the human pregnancy.

K J Moise1, C N Ou, B Kirshon, L E Cano, C Rognerud, R J Carpenter.   

Abstract

Little is known about the placental transfer of indomethacin in the human pregnancy. Twenty-six pregnant patients (gestational age, 29.4 +/- 0.5 weeks) were given a 50 mg oral dose of indomethacin 6.08 +/- 0.07 hours before 42 cordocenteses undertaken for standard indications. Maternal serum, fetal serum, and amniotic fluid levels were measured at the time of each procedure. Maternal indomethacin levels were not significantly different from corresponding fetal levels (218 +/- 21 vs 219 +/- 13 ng/ml). The maternal/fetal serum ratio (0.97 +/- 0.07) was not found to vary with gestational age (R = -0.07, p = 0.66). Fetal serum levels were significantly higher than corresponding amniotic fluid levels (219 +/- 16 vs. 21 +/- 2 ng/ml; p less than 0.001). The fetal/amniotic fluid ratio (10.0 +/- 1.2) did not vary with gestational age (R = 0.33, p = 0.11). Indomethacin crosses the human placenta easily throughout gestation; only small amounts of the unchanged drug are found in the amniotic fluid.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309841     DOI: 10.1016/0002-9378(90)90427-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

Review 1.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes.

Authors:  Sanjiv B Amin; Robert A Sinkin; J Christopher Glantz
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 3.  Cyclo-oxygenase (COX) inhibitors for treating preterm labour.

Authors:  Hanna E Reinebrant; Cynthia Pileggi-Castro; Carla L T Romero; Rafaela A N Dos Santos; Sailesh Kumar; João Paulo Souza; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2015-06-05

Review 4.  Effects of maternally administered drugs on the fetal and neonatal kidney.

Authors:  Farid Boubred; Mariella Vendemmia; Patricia Garcia-Meric; Christophe Buffat; Veronique Millet; Umberto Simeoni
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model.

Authors:  Michael G Gravett; Kristina M Adams; Drew W Sadowsky; Alexandra R Grosvenor; Steven S Witkin; Michael K Axthelm; Miles J Novy
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

6.  Neurodevelopmental outcome of premature infants after exposure to antenatal indomethacin.

Authors:  Sanjiv B Amin; Majeeda Kamaluddeen; Madhavi Sangem
Journal:  Am J Obstet Gynecol       Date:  2008-05-02       Impact factor: 8.661

Review 7.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

8.  Pharmacokinetics of indomethacin in pregnancy.

Authors:  Erik Rytting; Tatiana N Nanovskaya; Xiaoming Wang; Daria I Vernikovskaya; Shannon M Clark; Marlo Cochran; Susan M Abdel-Rahman; Raman Venkataramanan; Steve N Caritis; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

9.  Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus.

Authors:  Charles D Loftin; Darshini B Trivedi; Robert Langenbach
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2.

Authors:  C D Loftin; D B Trivedi; H F Tiano; J A Clark; C A Lee; J A Epstein; S G Morham; M D Breyer; M Nguyen; B M Hawkins; J L Goulet; O Smithies; B H Koller; R Langenbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.